BIOLARGO, INC.
BLGO · OTCMCIK 880242fmd_1PH7NH326NR6GBBAJDVW9SMEKSManufacturing · Chemicals & Allied ProductsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 1 | 2 | 2 | 3 | 6 | 12 | 18 | 8 |
| Cost of revenue | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 6 | 10 | 4 |
| Net interest income | – | – | – | – | – | – | (0) | (0) | (0) | (0) |
| Gross profit | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 6 | 8 | 3 |
| Research and development | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Selling, general and administrative | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 9 | 12 |
| Total operating expenses | – | 6 | 7 | 8 | 9 | 8 | 8 | 11 | 12 | 18 |
| Operating income | (5) | (6) | (6) | (7) | (8) | (7) | (5) | (5) | (4) | (15) |
| Interest expense | 3 | 4 | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 1 |
| Interest and investment income | – | – | – | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (3) | (4) | (4) | (5) | (2) | (0) | 0 | (0) | (0) | (0) |
| Income before taxes | – | – | – | – | – | – | – | – | (4) | (15) |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (4) | – |
| Net income | (8) | (10) | (11) | (11) | (10) | (7) | (5) | (5) | (4) | (15) |
| Net income to common shareholders | (8) | (9) | (10) | (11) | (8) | (7) | (4) | (4) | (2) | (12) |